The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the ...

Some telehealth companies that offered compounded GLP-1s have disappeared altogether. Others are pursuing strategies that ...

Hims & Hers Health surged after Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a reduced price ...

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

AstraZeneca’s AZN first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.10. Core earnings of $2.49 per share rose 21% year over year on ...

European pharmaceutical companies are pushing for higher drug prices across the EU, warning that current pricing policies are ...

European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...